Evidence map›Paper›PMID 23225251›Full record

ReviewCurrent hematologic malignancy reports2013

CARs in chronic lymphocytic leukemia -- ready to drive.

Chitra Hosing, Partow Kebriaei, William Wierda, Bipulendu Jena, Laurence J N Cooper, Elizabeth Shpall

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. The Application of CAR-T Cells in Haematological Malignancies.Archivum immunologiae et therapiae experimentalis · 2020
    Review
  2. Review
  3. Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.Journal of the National Cancer Institute · 2016
    Review
  4. Review
  5. Review
  6. Adoptive immunotherapy for cancer or viruses.Annual review of immunology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Chitra Hosing *Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Unit 423, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Partow Kebriaei *Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Unit 423, 1515 Holcombe Blvd, Houston, TX 77030, USA.
William WierdaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bipulendu JenaDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Laurence J N CooperDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth ShpallDepartment of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Unit 423, 1515 Holcombe Blvd, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
Specific Control of donor Anti-host AlloreactiviyU19CA100265 · NCI · DANA-FARBER CANCER INST · PI REISNER, YAIR · 2006 to 2008
$10.3M
Rebuilding Immunity for SurvivalP01CA100265 · NCI · DANA-FARBER CANCER INSTITUTE · PI NADLER, LEE MARSHALL · 2003 to 2005
$7.2M
Adoptive immunotherapy after umbilical cord blood transplantR01CA124782 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI COOPER, LAURENCE J.N. · 2007 to 2011
$2.0M
T-cell Therapy for B-lineage Acute Lymphoblastic LeukemiaR01CA141303 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI COOPER, LAURENCE J.N. · 2010 to 2014
$1.5M
Enhancing the efficacy of CD19-specific cord blood-derived T CellsR01CA120956 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI COOPER, LAURENCE J.N. · 2007 to 2011
$1.5M
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCYR33CA116127 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI COOPER, LAURENCE J.N. · 2010 to 2011
$1.4M
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCYR21CA116127 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI COOPER, LAURENCE J.N. · 2007 to 2008
$371k
NCI NIH HHS CA16672NCI NIH HHS P01 CA081534NCI NIH HHS P01 CA100265NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA116127NCI NIH HHS R01 CA120956NCI NIH HHS R01 CA124782NCI NIH HHS R01 CA141303NCI NIH HHS R21 CA116127NCI NIH HHS R33 CA116127NCI NIH HHS U19 CA100265
6 · The paper itself

Abstract

Adoptive transfer of antigen-specific T cells has been adapted by investigators for treatment of chronic lymphocytic leukemia (CLL). To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens (TAAs), robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve potency. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, these early-phase trials are demonstrating impressive anti-tumor effects, particularly for CLL patients, paving the way for multi-center trials to establish the efficacy of CAR(+) T cell therapy.

Indexed as

Adoptive TransferAntigens, NeoplasmClinical Trials as TopicHumansImmunotherapy, AdoptiveLeukemia, Lymphocytic, Chronic, B-CellMutant Chimeric ProteinsReceptors, AntigenReceptors, Antigen, T-CellT-LymphocytesAntigens, NeoplasmMutant Chimeric ProteinsReceptors, AntigenReceptors, Antigen, T-Cell

Identifiers

PMID23225251
PMCPMC3864912
OpenAlexW1995337370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.